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Thrombocytopenia is a very frequent disorder in the intensive care unit. Many etiologies should be searched, and
therapeutic approaches differ according to these different causes. However, no guideline exists regarding optimum
practices for these situations in critically ill patients. We present recommendations for the management of
thrombocytopenia in intensive care unit, excluding pregnancy, developed by an expert group of the French-Language
Society of Intensive Care (Société de Réanimation de Langue Française (SRLF), the French Language Group of Paediatric
Intensive Care and Emergencies (GFRUP) and of the Haemostasis and Thrombosis Study Group (GEHT) of the French
Society of Haematology (SFH). The recommendations cover six fields of application: definition, epidemiology, and
prognosis; diagnostic approach; therapeutic aspects; thrombocytopenia and sepsis; iatrogenic thrombocytopenia, with
a special focus on heparin-induced thrombocytopenia; and thrombotic microangiopathy.
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Introduction and presentation of the expert
recommendations of the French-language Intensive Care
Society (Société de Réanimation de Langue Française
(SRLF))
Thrombocytopenia is the hemostatic disorder that is
most frequently encountered in intensive care and is seen
in 41–66% of patients (close to 50% at admission). In
view of the mortality associated with thrombocytopenia,
the numerous associated pathological conditions seen in
intensive care, and the lack of recommended treatment
strategy, the SRLF has drawn up these recommendations.
An SRLF expert group drew up recommendations, giving
reasoned arguments for each of six fields of application
defined by the organizing committee, including pediatric
specificities. Each expert (or expert subgroup) then pre-
sented and justified the content and form of the proposed
recommendations, changes to which could be made during
the ensuing discussion. The revised recommendations were
then put to the vote. The purpose was not to impose a sin-
gle expert point of view for all the recommendations but to
delineate clearly the points of agreement that underpin the* Correspondence: vanderlinden.thierry@ghicl.net
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reproduction in any medium, provided the origrecommendations, as well as points of disagreement or in-
decision that may form the basis of future work.
Recommendations were scored according to an ap-
proach based on the RAND/UCLA Appropriateness
Method. After the first round of voting for each recom-
mendation (score 1 for complete disagreement or lack of
any proof to 9 for complete agreement or conclusive evi-
dence), the highest and lowest scores were eliminated,
and the score was taken as the median of the remaining
scores. The upper and lower bounds were then consid-
ered as “strong agreement” if they lay within the range
7–9 and “strong disagreement” in the range 1–3. Such
scores were considered definitive. Recommendations
whose scores were not within these two ranges were
voted on again, following the same principle. After this
second round of voting, the scores were taken as follows:
– Median and bounds within range [7–9] = “strong
agreement”
– Median and bounds within range [1–3] = “strong
disagreement”
– Median within range [7–9] with lower bound < 7 =
“weak agreement”
– Median within range [1–3] with upper bound > 3 =
“weak disagreement”
– Median within range [4–6] = “uncertainty”. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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system (Grading of Recommendations Assessment, De-
velopment and Evaluation) for rating clinical guidelines
(http://www.gradeworkinggroup.org/links.htm), the ori-
ginality of which stems primarily from three assertions.
First, characterization of the type of study alone (e.g.,
randomized or not) is insufficient to indicate the level of
proof of a study. Second, the risk/benefit ratio is taken
into account. Third, the exact wording of guidelines car-
ries clear implications for users: “should be done/
recommended. . .” (strong agreement) or “should not be
done/not recommended” (strong disagreement), “should
probably be done/is possible” (weak agreement), or
“should probably not be done/is possible not to do”
(weak disagreement).
Field 1: Definition – epidemiology – prognosis
1. Thrombocytopenia is defined by a platelet count
(PC) < 150 × 109/L (strong agreement).
2. In intensive care, pseudothrombocytopenia should
be discounted using in vitro agglutination of
platelets, by preparing a blood film, or, if necessary,
using a blood sample collected in a citrate tube
(strong agreement).
3. An etiological investigation is required to determine
the causes and underlying mechanisms of a PC <
100 × 109/L or a > 30% decrease in PC. It also can
be done for a drop in PC, independently of these
cutoffs, depending on the pathological context
(strong agreement).
4. A more than 30% drop in PC should probably be
considered to be associated with a poor prognosis
(weak agreement).
5. Changes in PC over time (duration, speed of
decrease or rise, etc.) should be considered to be
associated with the prognosis (strong agreement).
Field 2: Diagnostic approach
6. The underlying mechanisms and etiologies of
thrombocytopenia in intensive care are often
multiple, with peripheral causes predominating
(strong agreement).
7. Sepsis is the main etiology of thrombocytopenia in
intensive care and is usually associated with
disseminated intravascular coagulation (DIC) (strong
agreement).
8. Diagnosis of DIC should be based on both clinical
and biochemical criteria. International Society on
Thrombosis and Haemostasis (ISTH) and Japanese
Association for Acute Medicine (JAAM) scores can
be used to objectify DIC (scores in Additional file 1
and 2)(strong agreement).9. The clinical context should suggest the etiology of
thrombocytopenia in most cases in intensive care
(strong agreement).
10. In thrombocytopenia in intensive care, bone
marrow biopsy should not be performed routinely
but can be considered when there is no obvious
etiology or when other cell lineages are affected
(strong agreement).
11. Screening for antiplatelet antibodies is unjustified in
the initial diagnostic approach to thrombocytopenia
(strong agreement).
12. It is important to know which diagnoses of
thrombocytopenia justify special investigations and
prompt initiation of specific treatments (notably
thrombotic microangiopathy [TMA], macrophage
activation syndrome, catastrophic antiphospholipid
syndrome) (strong agreement).
Field 3: Therapeutic aspects
13. In intensive care, bleeding severity can be graded
with a 5-point scale used in the literature
[0: no hemorrhage; 1: slight hemorrhage; 2: patent
blood loss not requiring red cell transfusion;
3: blood loss requiring red cell transfusion; 4:
hemorrhage with considerable morbidity] (strong
agreement).
14. For a similar PC, central thrombocytopenia
probably involves a greater risk of bleeding than
peripheral thrombocytopenia. Bleeding
complications occur above all with central
thrombocytopenia < 20 × 109/L (weak agreement).
15. The decision to treat thrombocytopenia should be
based on the PC but also on the: Presence of active bleeding (type, potential
severity),
 Mechanism of thrombocytopenia (central or
peripheral),
 Etiology,
 Risk of thrombosis,
 Risk of hemorrhage (platelet disorders, invasive
procedures or surgery), and
 Associated treatments (strong agreement).16. If platelet transfusion is necessary, pooled standard
platelet units should be used, except for
allo-immunized patients, those receiving treatment
for blood disorders, and those with blood disorders,
all of whom should be given aphaeresis platelet
concentrate (single donor)(strong agreement).
17. The number of platelet units transfused should be
prescribed depending on body weight: 1 platelet
unit (0.5 to 0.7 × 1011 platelets) per 7 kg body
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18. ABO/Rh1 (D)-compatible platelets should be
preferred for transfusion (strong agreement).
19. There is no need to calculate the percent platelet
recovery (strong agreement).
20. Depending on the context and in the event of
severe risk of hemorrhage, it is probably necessary
to measure the PC in the hour following the end of
platelet transfusion (weak agreement).
21. The risk of hemorrhage in thrombocytopenia
should not be defined by the PC alone, but by a
combination of PC < 50 × 109/L, the clinical
situation and factors that may influence primary or
secondary hemostasis (strong agreement).
22. In intensive care, prophylactic platelet transfusion
should not be routine when the PC > 20 × 109/L in
central or peripheral thrombocytopenia (strong
agreement).
23. In intensive care, prophylactic platelet transfusion
should probably be done in central
thrombocytopenia when the PC < 20 × 109/L
(weak agreement).
24. In intensive care, in the case of severe hemorrhage,
platelet transfusion is recommended when the
PC ≤ 50 × 109/L (strong agreement).
25. In intensive care, platelet transfusion is probably
necessary when the PC ≤ 50 × 109/L in the following
situations:
– Severe sepsis, with risk of severe hemorrhage or
use of anticoagulant,
– Invasive procedure,
– Pre- or postsurgical setting (weak agreement).
26. In intensive care, platelet transfusion is probably
necessary when the PC ≤ 100 × 109/L: after surgery
of the central nervous system, liver, eye, and large
blood vessels; in patients with polytrauma (weak
agreement).;
27. In intensive care, prophylactic platelet transfusion is
not recommended in the following situations:
posttransfusion purpura, thrombotic
thrombocytopenic purpura (TTP), catastrophic
antiphospholipid syndrome, hemolytic-uremic
syndrome (HUS), heparin-induced
thrombocytopenia (HIT) (strong agreement).
28. In intensive care, prophylactic platelet transfusion is
probably not recommended in cases of DIC (weak
agreement).
29. In intensive care, the risk of hemorrhage (severity of
thrombocytopenia, associated platelet disorders)
and the risk of thromboembolic events should be
assessed before deciding to administer antiplateletdrugs, curative anticoagulant treatment, or
preventive anticoagulant treatment to
thrombocytopenic patients (strong agreement).
30. Antithrombotic prophylaxis using unfractionated
heparin (UFH) or low-molecular-weight heparin
(LMWH) should probably be prescribed routinely
in all adult patients admitted to intensive care,
except when the PC < 30 × 109/L or there is a major
risk of hemorrhage (strong agreement).
31. Any interruption of antiplatelet drugs in an
intensive care patient should be as short as possible,
especially if the patient has a drug-eluting stent
(strong agreement).
32. When a patient admitted to intensive care is already
taking antiplatelet drugs, these should probably be
withdrawn if there is a risk of hemorrhage (PC <
50 × 109/L, other risk factors, etc.) (weak agreement).
Field 4: Thrombocytopenia and sepsis
34. Use of immunoglobulins in thrombocytopenic
patients with sepsis is not recommended
(strong agreement).
35. Thrombocytopenia is very frequent in infectious
purpura fulminans, because DIC is more severe
that in other septic shock etiologies in children
(strong agreement).
36. Apart from immediate parenteral administration of
a first dose of antibiotic as soon as infectious
purpura fulminans is suspected, there is no
recommended treatment specific to infectious
purpura fulminans compared with other septic
shock etiologies in children(strong agreement).
37. For infectious thrombocytopenia, routine
administration of treatments specific to hemostasis
(protein C, antithrombin III, anticoagulants,
fibrinolytics) is not recommended because of the
high risk of hemorrhage. It can be considered in the
most severe cases, always following individualized
reassessment of the risk/benefit ratio (strong
agreement).
Field 5: Iatrogenic thrombocytopenia
38. Etiological diagnosis of drug-induced
thrombocytopenia in intensive care should be
guided by its origin (peripheral versus central) and
mechanism (immune versus nonimmune) (strong
agreement).
39. HIT should probably be suspected for any
thrombocytopenia in intensive care (weak
agreement).
40. Drug-induced thrombocytopenia should be treated
by withdrawal of the drug concerned, which
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41. In very severe forms (PC < 5× 109/L or with
life-threatening bleeding) of drug-induced
thrombocytopenia with an immune mechanism,
intravenous immunoglobulins or even
plasmapheresis is possible (weak agreement).
42. Thrombocytopenia after chemotherapy most often
is linked to myelosuppression, its severity and
duration depends on the type and dose of cytostatic
drugs used and on the initial PC (strong agreement).
43. In central thrombocytopenia after chemotherapy,
platelet transfusion is recommended for a
PC < 20 × 109/L with signs of bleeding and should
be routine for a PC < 10 × 109/L (strong agreement).
44. Severe thrombocytopenia in the multiparous
woman or the patient who has received multiple
transfusions is indicative of posttransfusion purpura,
which can be treated with intravenous
immunoglobulins (strong agreement).
45. For patients at high risk of hemorrhage without
liver failure, citrate should be the anticoagulant of
choice for intermittent and continuous renal dialysis
(strong agreement).
46. Extracorporeal membrane oxygenation (ECMO) or
extracorporeal life support (ECLS) in intensive care
is always accompanied by a decrease in PC and
requires anticoagulation, generally with low doses of
heparin (5–20,000 IU/day) for the first few days,
with dosage adjustment according to hemostasis
tests (strong agreement).
Heparin-induced thrombocytopenia
47. Whichever heparin is used (UFH or LMWH),
baseline PC should be measured on initiation or
during the first 24 hours of treatment (strong
agreement).
48. PC should probably be measured twice in any
patient exposed to UFH during the past 3 months,
first upon initiation of heparin therapy (UFH or
LMWH) and then the next day (weak agreement).
49. In intensive care, PC should be measured twice a
week during the first 3 weeks of heparin therapy
(UFH or LMWH)(strong agreement).
50. Warkentin 4-T score should be used to assess the
probability of HIT, even though it has not been
specifically validated in intensive care (see
Additional file 3) (strong agreement).
51. In patients with a Warkentin 4-T score < 2,
a laboratory test of HIT should probably not be
done (weak agreement).
52. Two types of diagnostic laboratory tests should
probably be combined in any patient with suspectedHIT: one functional and one immunoenzymatic
(ELISA) to screen for antiheparin PF4 antibodies
(weak agreement).
53. Heparin should be excluded if there is a history of
HIT. A nonheparin anticoagulant is recommended
(strong agreement).
54. If there is a history of HIT, danaparoid is the
first-line anticoagulant in intensive care
(strong agreement).
55. In a patient with suspected HIT and a Warkentin
4-T score ≥ 2, withdrawal of heparin should
probably be considered (weak agreement).
56. In a patient with suspected HIT and a Warkentin
4-T score ≥ 4, heparin should be replaced
immediately by an empirical nonheparin treatment
at curative dosage: danaparoid sodium, lepirudin, or
even bivalirudin (strong agreement).
57. In intensive care, fondaparinux is probably not
recommended as replacement therapy during the
acute phase of HIT (weak agreement).
58. In intensive care, the introduction of vitamin K
antagonists during the acute phase of HIT is
contraindicated (strong agreement).
Field 6: Thrombotic microangiopathy
59. Thrombocytopenia associated with mechanical
hemolytic anemia should suggest TMA, even in the
absence of organ failure (strong agreement).
60. In any patient with suspected TMA, the blood
samples (2 dry tubes and 2 EDTA tubes) for
etiological investigation (ADAMTS13 activity,
complement, autoimmunity, HIV) should be
collected before any treatment, without delaying its
initiation (strong agreement).
61. The first-line treatment of TMA should be based on
emergency plasma exchange (PE) (rate 60 mL/kg).
If PE is not initially possible, plasma should be
infused at 20 mL/kg when possible (strong
agreement).
62. In TMA, PE should be continued daily for at least 5
to 7 days until the PC normalizes and is stable for
at least 48 hours. The rate of PE is lowered
progressively, on a case-by-case basis (strong
agreement).
63. In adults and children with TMA, platelet
transfusion is strictly contraindicated unless there is
life-threatening bleeding (strong agreement).
64. In adults with TMA, an invasive procedure is not
an indication for routine prophylactic platelet
transfusion because of potentially lethal adverse
effects (strong agreement).
65. In children with TTP, an invasive procedure is
probably not an indication for routine prophylactic
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adverse effects (weak agreement).
66. In children with HUS, routine prophylactic platelet
transfusion should be restricted to invasive
procedures that have a high risk of hemorrhage
(strong agreement).
67. For the specific treatment of TMA, infusion of
heparin, fibrinolytics, prostacyclin, or vitamin E is
useless, even dangerous. There is no evidence for
the efficacy of antiplatelet drugs (strong agreement).
68. In TTP, patients should be routinely monitored and
tested for myocardial ischemia (strong agreement).
69. In TTP, methylprednisolone can be used if not
contraindicated, in combination with PE
(strong agreement).
70. In congenital TTP, specific treatment should be
based on administration of plasma (10 mL/kg every
2 to 4 weeks) (strong agreement).
71. In HUS, stools or rectal swabs should be tested for
Shiga toxin-producing E. coli (STEC) using culture
on MacConkey agar and polymerase chain reaction
to test for Shiga toxin (strong agreement).
72. In HUS, if no STEC is found in the stools, the
serum should probably be tested for anti-LPS IgM
of the most frequent serogroups of STEC
(weak agreement).
73. Children with HUS should be transferred to a
specialized department (nephrology or intensive
care) for discussion of prompt initiation of
hemodialysis (strong agreement).
74. In adults and children with HUS caused by STEC,
PE has not proven effective and should probably not
be recommended (weak agreement).
75. PE should probably be used in HUS caused by
STEC with central neurological involvement
(weak agreement).
76. In HUS caused by Streptococcus pneumoniae,
administration of plasma is probably
contraindicated and only washed packed red blood
cells or platelets should be used when the
agglutination test is positive(weak agreement).
77. First-line treatment of atypical HUS should be
emergency PE (rate 60 mL/kg). If PE is not initially
possible, plasma should be infused at 10–20 mL/kg
when possible (strong agreement).
78. If the response to first-line treatment is suboptimal,
immunomodulators should be considered
(rituximab in acquired TTP, eculizumab in atypical
HUS), in collaboration with a reference center.
Suboptimal response is defined as follows:
– Atypical HUS: failure to correct
thrombocytopenia and/or to improve renal
function at day 5 of standard treatment– Acquired TTP: PC not doubled by day 5 of
standard treatment or diseaseprogression
(increased thrombocytopenia or onset of organ
damage) duringintensive first-line treatment or
on reducing the frequency of PE (strong
agreement).
79. In the absence of treatment, the prognosis of
atypical HUS is guarded (death in 10% of cases and
progression to terminal renal failure in 50% of
cases), particularly when there is factor H mutation
(death or terminal renal failure immediately or
within 1 year in 70% of cases) (strong agreement).
Uncertainty
The experts’ scores for the following statements lay within
a range of uncertainty.
 PC < 150 × 109/L is associated with an unfavorable
prognosis.
 In intensive care, prophylactic platelet transfusion
should be performed in cases of peripheral
thrombocytopenia < 10 × 109/L.
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